Nebenwirkungen · Mounjaro
Mounjaro 2.5 mg solution for injection in pre-filled pen Mounjaro 5 mg solution for injection in pre-filled pen Mounjaro 7.5 mg solution for injection in pre-filled pen Mounjaro 10 mg solution for injection in pre-filled pen Mounjaro 12.5 mg solution for injection in pre-filled pen Mounjaro 15 mg solution for injection in pre-filled pen Mounjaro 2.5 mg solution for injection in vial Mounjaro 5 mg solution for injection in vial Mounjaro 7.5 mg solution for injection in vial Mounjaro 10 mg solution for injection in vial Mounjaro 12.5 mg solution for injection in vial Mounjaro 15 mg solution for injection in vial Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12
HOS-148208 · Präparat HOS-099850
In SURPASS-CVOT, at month 36, treatment with tirzepatide resulted in mean increases from baseline in pancreatic amylase of 29 % and lipase of 28 %.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-21T13:40:00Z · SHA-256 8d75eff2f10bd886e04a9cae39b5a53d6eea8dc5f9d2d23738f4b6def2646875 · Passage 59298e67ad0615a0b0e43f2d0298abdfd9b4a381bad942639f49cbe4301525e5 · Zeichen 12714–12861 im Abschnitt